We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Roche Introduces Enhanced Whole Exome Sequencing Solution

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Introduces Enhanced Whole Exome Sequencing Solution"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

This is a comprehensive whole exome sequencing (WES) solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs.

"The release of the SeqCap EZ MedExome Target Enrichment Kit is an example of Roche Sequencing's commitment to further the evolution of genomic medicine," said Rebecca Selzer, President of Roche NimbleGen. "Immense interest in this design from our customers worldwide led to initiation of an early product evaluation process resulting in more than 40 evaluations across 11 countries globally prior to launch. This technology puts some of the most powerful tools of modern genomics to use in more laboratories around the world and is an invaluable asset in furthering the research of disease-associated mutations, while minimizing the need for costly retesting and follow-up sequencing."

Pekka Ellonen, Head of the Sequencing Unit for the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, said, "We have evaluated a number of target enrichment systems for whole exome sequencing. The SeqCap EZ MedExome has demonstrated the best on-target read rates and evenness of coverage. Especially the clinically relevant exons are well covered. The protocol is straightforward yet flexible and the overnight hybridization further improves our response time. We are very excited to be an early adopter of this Roche product."